What Rapamycin Longevity Lab does

Rapamycin Longevity Lab is a Gothenburg, Sweden-based research coordination entity founded in 2024 by Krister Kauppi and operated as part of Venture Plant AB, a Swedish private limited company. The organization has 1-10 employees and does not perform laboratory work itself; instead, it coordinates and funds high-throughput longevity screening of mTOR inhibitors through a strategic partnership with Ora Biomedical, whose WormBot-AI platform combines robotics and AI to perform massively high-throughput longevity analysis in Caenorhabditis elegans (roundworms). The lab's core initiative is a coordinated research project to screen 601 mTOR inhibitors for healthy lifespan effects in C. elegans, split into two subprojects with budgets of $50,000 (Subproject 1, fully funded) and $60,000 (Subproject 2, in active fundraising), with all resulting data released publicly through Ora Biomedical's database within three months of project funding.

The lab's broader product surface includes the Longevity Intervention Database (LID), a public database cataloging intervention effects across species and strains; the Longevity Wormbot Program (LOOP), an annual recurring screening cadence; and the Rapamycin Longevity Series podcast featuring interviews with longevity researchers such as Matt Kaeberlein, Joan Mannick, Brian Kennedy, and Mikhail Blagosklonny. Marketing and distribution are community-driven, leveraging YouTube live streams, the podcast, social media, and media partnerships with Lifespan.io and Rapamycin.news.

The business model is community-driven philanthropy rather than commercial revenue capture. The lab does not charge for membership or take commissions on funds raised. Instead, it recruits community members (targeting 3,000 for Project 2) and accepts tiered sponsorships (Gold $10,000, Silver $5,000, Bronze $1,000) that flow directly to Ora Biomedical for screening work. Customers are effectively longevity enthusiasts, mTOR inhibitor community members, and longevity researchers who fund and consume the lab's publicly available outputs. The organization is certified as a Vitalist Organization by Vitalism.io and operates without disclosed commercial revenue.

Name

Rapamycin Longevity Lab

Legal name

Venture Plant AB

Website

https://rapamycinlongevitylab.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Gothenburg-based research coordinator founded by Krister Kauppi in 2024 that raises sponsorship funds and partners with Ora Biomedical to coordinate high-throughput screening of 601 mTOR inhibitors for longevity in C. elegans, operating a public longevity intervention database and educational podcast.

Ownership category

akta.pro rank

Product category

Longevity Research Coordination

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

akta.pro primary industry

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Longevity research
• MTOR inhibitor screening
• Research coordination
• Biomedical research funding
• Healthspan science

Headquarters

HQ city

Gothenburg

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Research Project Funding/Sponsorships: Funding is raised through sponsorship tiers (Gold $10k, Silver $5k, Bronze $1k) for specific mTOR inhibitor screening projects. All funds go directly to Ora Biomedical for screening work. Rapamycin Longevity Lab coordinates and leads projects without taking commission.
2. Free Membership Program: Free membership program providing exclusive project updates and information. Revenue not directly generated; serves as community-building mechanism for future fundraising.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Rapamycin Longevity Lab coordinates community-funded longevity research projects, most prominently partnering with Ora Biomedical to screen 601 mTOR inhibitors for lifespan effects in the roundworm Caenorhabditis elegans using the WormBot-AI platform. The lab also maintains a publicly accessible Longevity Intervention Database (LID) and produces the Rapamycin Longevity Series podcast for educational outreach.

Product overview

Rapamycin Longevity Lab operates as a research coordination organization focused on accelerating longevity science around Rapamycin and mTOR inhibitors. The core offering consists of the mTOR Inhibitor Screening Project, which partners with Ora Biomedical to screen 601 mTOR inhibitors using the WormBot-AI platform. This is supported by the Longevity Intervention Database (LID), a public database aggregating lifespan data across species and interventions. The organization also conducts the annual Longevity Wormbot Program (LOOP) for ongoing candidate testing, and produces the Rapamycin Longevity Series Podcast for educational outreach.

Differentiator

Problem solved

Functional benefit

Brands

• Longevity Intervention Database (LID): A comprehensive database of longevity interventions featuring data on lifespan effects across multiple species including Caenorhabditis elegans, Drosophila, mice, and rats.
• Rapamycin Longevity Series

Products and services

• mTOR Inhibitor Screening Project Research initiative coordinated with Ora Biomedical to conduct comprehensive lifespan analysis of 601 mTOR inhibitors in the roundworm Caenorhabditis elegans, using the WormBot-AI platform for high-throughput screening. Sponsored by individual contributors and longevity-focused companies.
• Longevity Intervention Database (LID) Publicly accessible online database cataloging longevity interventions and their effects on median and maximum lifespan across different species, strains, and genders, with filtering capabilities.
• Longevity Wormbot Program (LOOP) Annual screening program that continues the partnership with Ora Biomedical to test selected mTOR inhibitors at multiple doses in roundworms, identifying optimal candidates for further longevity research.
• Rapamycin Longevity Series Podcast Podcast series featuring expert interviews with scientists and physicians (including Joan Mannick, Brian Kennedy, Mikhail Blagosklonny, Matt Kaeberlein, and others) discussing Rapamycin, mTOR inhibition, and longevity research topics.

Quantifiable outcome

• 601 mTOR inhibitors screened for lifespan effects in C. elegans
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core and minor.

• Ora BiomedicalcoreTechnology or IntegrationStrategic partnership to coordinate lifespan analysis of 601 mTOR inhibitors using Ora Biomedical's WormBot-AI technology. Matt Kaeberlein, co-founder of Ora Biomedical and world-leading Rapamycin researcher, provides scientific expertise. The WormBot platform combines robotics and AI for massively high-throughput longevity screening in roundworms. Rapamycin Longevity Lab coordinates and leads the research project while all screening work is conducted by Ora Biomedical. All resulting data will be publicly available.
• Lifespan.iominorGTM or Marketing PartnerMedia supporter for the mTOR inhibitor screening project. Provides promotional support and visibility within the longevity community.
• Rapamycin.newsminorGTM or Marketing PartnerMedia supporter providing coverage and visibility for longevity research projects.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• AgelessRx: Telehealth provider of rapamycin and other longevity interventions, listed as a sponsor of Rapamycin Longevity Lab. Comparable focus on translating mTOR science into accessible longevity offerings for consumers.
• NewLimit: Sam Altman-backed longevity biotech using epigenetic reprogramming. Operates in adjacent longevity biology space with overlapping founder/funder networks in the longevity community.
• Loyal for Dogs: FDA-conditional-approved developer of a longevity drug for dogs targeting mTOR. Operates in the same mTOR-inhibitor longevity regulatory and scientific frontier, providing a downstream translational reference point for the lab's C. elegans work.
• Healthspan: Longevity-focused consumer health company sponsoring the lab's first subproject. Both target the same health-conscious longevity audience and benefit from advances in mTOR-inhibitor longevity research.

Direct peers

• Ora Biomedical: Core technology partner running WormBot-AI screening. Both organizations are focused on mTOR inhibitor longevity research in C. elegans and share scientific leadership via Matt Kaeberlein, making Ora Biomedical the closest functional peer.
• Lifespan.io: Longevity research media and crowdfunding platform that has partnered with Rapamycin Longevity Lab. Both operate community-driven funding models for longevity science and share overlapping sponsor bases in the rapamycin/mTOR space.
• OpenCures: Sponsor of the lab's Subproject 1 and a community-driven open-science longevity research organization. Comparable mission of accelerating longevity research through distributed funding and open data.

Broad incumbents

• Insilico Medicine: AI-driven drug discovery company with active aging and longevity pipeline. Comparable in combining AI and high-throughput biology to identify geroprotective compounds, including those targeting mTOR pathways.
• Calico Life Sciences: Alphabet-backed longevity research company pursuing aging biology broadly. Comparable in mission to extend healthy human lifespan and has the resources to run large-scale compound screening programs that could overlap with the lab's mTOR focus.
• Altos Labs: Well-capitalized longevity biotech pursuing cellular rejuvenation across multiple biological pathways including mTOR. Operates in the same longevity biology space with vastly greater resources, making it a strategic competitor for talent and attention.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@RapamycinLongevityLab
• Xx.com/omipalRLL
• LinkedInlinkedin.com/company/rapamycin-longevity-lab

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rapamycin Longevity Lab